LIBX-A402 (Compound 15b) is a selective ACSL4 inhibitor with an IC50 of 0.33 µM. It notably safeguards MDA-MB-231 and LUHMES cells from ferroptosis. LIBX-A402 is applicable in research focused on cancer, ischemia-reperfusion injury, and neurodegenerative disorders such as Parkinsons disease.
Target:
Ferroptosis
* VAT and and shipping costs not included. Errors and price changes excepted
